Joint Injections for Knee Pain — PRP, Cell Factor & the Evidence

Pain management · Evidence review

By Jamie Walston · Beverly Hills Rejuvenation Center · Reviewed by the BHRC Clinical Team

Corticosteroid, hyaluronic acid, PRP and cell-based injections for knee osteoarthritis — what the guidelines actually say, what the largest trials found, and why the evidence and the marketing point in different directions.

1. Before any injection: the thing every guideline puts first

Every major guideline — OARSI, AAOS, the American College of Rheumatology — puts the same things at the top, and none of them involve a needle. Structured land-based exercise, self-management education, and weight management for knee osteoarthritis. AAOS grades supervised, unsupervised and aquatic exercise as a strong recommendation over no exercise; self-management programmes likewise; sustained weight loss at moderate.

We are going to be honest about why. It is not because the effect size is large. The 2024 Cochrane review of exercise for knee osteoarthritis found, on a 0–100 scale, improvements of about 13.1 points for pain and 12.5 for function against no treatment — and the authors explicitly described these as “of uncertain clinical importance,” often falling below the minimal important differences of 12 and 13 points.

Exercise is first-line because it has the best risk–benefit ratio in the category — not because it works dramatically. Everything that comes after it has either a smaller effect, a larger risk, or both.

That framing matters because it sets a realistic bar. If a treatment beats a 13-point improvement with an acceptable risk profile, it is worth considering. If it does not, it is worth asking why you would pay for it.

2. Corticosteroid — the one that definitely works, briefly

Intra-articular corticosteroid is the best-established injection for knee osteoarthritis, and both AAOS and ACR recommend it. The Cochrane review quantified exactly how long it lasts, and the shape of that curve is the whole story.

So: a real, moderate effect for a few weeks, fading to nothing by six months. That is a perfectly good reason to have one — before a holiday, to break a pain cycle that is stopping you exercising, to buy time before a planned procedure. It is not a good reason to have four a year for a decade.

Which brings up the cartilage question. A 2017 JAMA trial randomised 140 patients to triamcinolone or saline every twelve weeks for two years. The steroid group lost more cartilage (−0.21 mm versus −0.10 mm, a between-group difference of −0.11 mm) and showed no significant pain advantage over saline at two years. A fair criticism is that quarterly injections for two years is more aggressive than typical practice. But it is the reason repeated steroid injection is now approached cautiously, and the reason a good provider will ask how many you have already had.

3. Hyaluronic acid — where the guidelines genuinely disagree

Viscosupplementation — injecting hyaluronic acid to supplement the joint’s own lubricating fluid — is widely offered and widely covered by insurance. The evidence is worse than its popularity suggests, and the guidelines do not agree with each other.

The two largest meta-analyses point the same way, and the pattern in them is instructive:

• Rutjes 2012 — 89 trials, 12,667 adults. Overall effect −0.37. But when restricted to large trials with blinded outcome assessment (18 trials, 5,094 patients) the effect fell to what the authors called “a clinically irrelevant effect size” of −0.11. Serious adverse events were increased, relative risk 1.41.
• Pereira 2022, BMJ — 24 large placebo-controlled trials, 8,997 patients. Pain effect −0.08, about 2.0 mm on a 100 mm scale, against a threshold for a meaningful difference of −0.37. Serious adverse events 3.7% versus 2.5%. The authors’ word for the evidence was “strong conclusive.”

The pattern to notice: in both analyses, the benefit shrinks as trial quality and blinding improve. That is the signature of a placebo effect plus publication bias, and it recurs throughout this field. Keep it in mind for the next section.

4. PRP — the honest version, which is complicated

Platelet-rich plasma is your own blood, spun down to concentrate the platelets and the growth factors they carry, then injected into the joint. It is popular, it is expensive, and the evidence about it is genuinely contradictory. Here is what that contradiction actually looks like.

What the guidelines say

“Limited” is AAOS’s lowest evidence tier above expert consensus. OARSI’s stated reason for its strong recommendation against was “extremely low quality” evidence and the absence of standardised formulations. ACR cited heterogeneity of preparations and failure to demonstrate clinical benefit.

The trial that matters most

RESTORE (JAMA 2021) is the highest-quality knee osteoarthritis trial of PRP: 288 participants, leukocyte-poor PRP, three weekly intra-articular injections, twelve-month follow-up against placebo.

For tendon problems the picture is similar. The ATM trial (JAMA 2021) randomised 240 people with chronic Achilles tendinopathy to PRP or a sham needle. At six months the difference was −2.7 points on a 100-point scale, against a minimal important difference of 12. A 2024 meta-analysis of six trials found no benefit at three months, six months or one year, and noted a funnel plot suggesting publication bias — “which typically inflates the apparent benefit of novel interventions.”

So why do so many studies say it works?

This is the part worth understanding, because it explains the whole field. AAOS’s own technology overview on PRP found that across 8 high-quality placebo-controlled studies and 25 studies against hyaluronic acid, PRP did show statistically significant pain improvements at timepoints up to twelve months — while showing no significant effect on cartilage thickness or knee strength. Their conclusion was that “each product remains weakly supported by heterogeneous data on small patient cohorts.”

The reconciliation: pooled analyses of many small trials favour PRP; the largest and best-blinded individual trials do not. PRP is not one intervention — preparations vary in platelet concentration, leukocyte content, whether the platelets are activated, injection volume and number of injections. Different meta-analyses reach opposite conclusions depending on what they include. That is not a conspiracy; it is what an unstandardised intervention studied in small trials looks like.

Three things that follow from this, which we hold ourselves to. PRP is not FDA-approved as a treatment for osteoarthritis or tendinopathy. No orthobiologic has been shown to regenerate cartilage — RESTORE found no difference in cartilage volume and AAOS found no significant effect on cartilage thickness, so words like “regenerates,” “rebuilds cartilage” or “reverses arthritis” are not supported by anything we could find. And before-and-after images or patient testimonials are not evidence: the placebo arms in both RESTORE and ATM improved substantially too.

5. Cell Factor and the regenerative category

Cell Factor is a growth-factor concentrate derived from your own blood, sitting in the same broad category as PRP. We offer it, and we are going to describe it the same way we describe PRP, because the evidence situation is the same or thinner.

OARSI and ACR both recommend against cell-based injections for knee osteoarthritis. AAOS does not address them. There is no orthobiologic in this category with the evidence base that corticosteroid has, and none that has demonstrated cartilage regeneration in a controlled trial.

What that means for how we position it: unproven and elective, priced transparently, and offered only after the core treatments every guideline specifies — exercise, weight management, self-management education, appropriate medication — have genuinely been tried. Not as a first resort, and not as an alternative to the things that are known to help. Our Cell Factor article goes into what it is and what the evidence shows in more detail, including where our own website’s description needed correcting.

6. The option with the strongest recent evidence, which nobody markets

Worth knowing, because it cuts against a blanket-sceptic reading of this article: genicular nerve radiofrequency ablation has the strongest recent supporting evidence of any interventional option for knee pain. A 2026 Bayesian network meta-analysis covering 29 studies and 2,285 participants ranked it highest for effectiveness against sham, intra-articular injections and chemical neurolysis — at one month (86.3%), three months (75.3%), six months (74.3%) and twelve months (75.0%), measured as the proportion achieving at least a 50% or 2-point pain reduction.

The caveats are real: a majority of the included studies were observational, and AAOS’s grade for denervation therapy remains “Limited.” But if the question is “what has the best evidence among the interventional options,” the honest answer is not PRP. It is a procedure that treats the nerves carrying the pain signal rather than the joint itself — which is a different goal, and not one every patient wants.

7. How to sequence this

The reason the sequence matters is not bureaucratic. Injections work better in people who are also moving; and an injection that buys six weeks of reduced pain is far more valuable if those six weeks are spent rebuilding quadriceps strength than if they are spent waiting for the next injection.

What to ask before you book an injection

• What exactly are you injecting, and what is the evidence for it in my specific problem?
• Is this FDA-approved for this use, or is it unproven and elective?
• How many corticosteroid injections have I had in this joint, and does that change your recommendation?
• What are we expecting, by when, and how will we know if it worked?
• What happens if it does not work — what is the next step?
• Have we actually done the exercise and weight-management part properly, or are we skipping it?

A provider who welcomes those questions is the one you want. Our joint injection page for West Los Angeles covers what the appointment itself involves, and the joint injections service page has the full picture across locations.

Where we do this

Joint injections and provider-led pain management run out of West Los Angeles and Summerlin, with assessment available at all six locations. Every plan starts with a conversation about what has already been tried, because that determines what makes sense next.

Questions we get asked

Keep reading

• Joint injections at BHRC
• Joint injections and non-surgical pain management in West LA
• Cell Factor — what it is and what the evidence shows
• PRP and PRF injections — cost and what to expect
• Cell Factor for joints
• Pain management without surgery or opioids
• Provider-led protocols and medical supervision

Book at any of our six locations

References

1. American Academy of Orthopaedic Surgeons — Management of osteoarthritis of the knee (non-arthroplasty), 3rd edition — clinical practice guideline, 31 August 2021. aaos.org
2. Bannuru RR, Osani MC, Vaysbrot EE, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019;27:1578–1589. pubmed.ncbi.nlm.nih.gov
3. Kolasinski SL, Neogi T, Hochberg MC, et al. — 2019 American College of Rheumatology / Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol 2020;72(2):220–233. pubmed.ncbi.nlm.nih.gov
4. Lawford BJ, Hall M, Hinman RS, et al. — Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev 2024, Issue 12, CD004376.pub4. cochranelibrary.com
5. Jüni P, Hari R, Rutjes AWS, et al. — Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev 2015, CD005328. cochranelibrary.com
6. McAlindon TE, LaValley MP, Harvey WF, et al. — Effect of intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis. JAMA 2017;317(19):1967–1975. jamanetwork.com
7. Rutjes AWS, Jüni P, da Costa BR, et al. — Viscosupplementation for osteoarthritis of the knee: a systematic review and meta-analysis. Ann Intern Med 2012;157(3):180–191. pubmed.ncbi.nlm.nih.gov
8. Pereira TV, Jüni P, Saadat P, et al. — Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis. BMJ 2022;378:e069722. bmj.com
9. Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of intra-articular platelet-rich plasma vs placebo injection on pain and medial tibial cartilage volume in patients with knee osteoarthritis: the RESTORE randomized clinical trial. JAMA 2021;326(20):2021–2030. jamanetwork.com
10. Kearney RS, Ji C, Warwick J, et al. — Effect of platelet-rich plasma injection vs sham injection on tendon dysfunction in patients with chronic midportion Achilles tendinopathy: the ATM randomized clinical trial. JAMA 2021;326(2):137–144. jamanetwork.com
11. Barreto RB, et al. — Does platelet-rich plasma improve outcomes in Achilles tendinopathy? A systematic review and meta-analysis. Clin Orthop Relat Res 2024;483(5):779–790. pubmed.ncbi.nlm.nih.gov
12. Quazi SJ, et al. — Comparative effectiveness of genicular nerve radiofrequency ablation for chronic knee pain: a systematic review with Bayesian network meta-analysis. Pain Medicine 2026;27(6):635–648. academic.oup.com
13. Dowell D, Ragan KR, Jones CM, et al. — CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep 2022;71(3):1–95. cdc.gov

Beverly Hills Rejuvenation Center. This content is for general education and does not create a physician-patient relationship or constitute medical advice. Joint injections are medical procedures requiring assessment by a qualified provider. Platelet-rich plasma and cell-based preparations are not FDA-approved for the treatment of osteoarthritis or tendinopathy; they are offered as elective treatments and described here as unproven, consistent with the guideline positions cited. Nothing in this article should be read as a claim that any injection regenerates cartilage or reverses osteoarthritis. If you have persistent joint pain, start with an assessment — not with a treatment. Candidacy, dosing, results and pricing vary by person and are confirmed at a free consultation. Reviewed by the BHRC clinical team.